JMP Securities analyst Constantine Davides maintained a Buy rating on Privia Health Group (PRVA – Research Report) today and set a price target of $29.00.
Constantine Davides has given his Buy rating due to a combination of factors that highlight Privia Health Group’s strong performance and promising outlook. The company’s recent financial results exceeded expectations, with key metrics such as Practice Collections and GAAP revenue showing significant year-over-year growth. Additionally, the number of implemented providers and attributed lives surpassed estimates, indicating robust expansion in their healthcare platform.
Furthermore, Privia Health demonstrated improved profitability, with Care Margin and adjusted EBITDA both exceeding projections. The company’s forward-looking guidance for 2025 suggests continued growth in Practice Collections and adjusted EBITDA, supported by a capital-efficient operating model and a diversified platform. These factors, along with the company’s ability to convert a high percentage of adjusted EBITDA to free cash flow, underpin the positive outlook and justify the Buy rating.
Davides covers the Healthcare sector, focusing on stocks such as Evolent Health, Option Care Health, and US Physical Therapy. According to TipRanks, Davides has an average return of -27.8% and a 31.03% success rate on recommended stocks.